Combined Phacoemulsification and Diode Laser Therapy in Chronic Angle Closure Glaucoma

Angle Closure Glaucoma Clinical Trial

Official title:

Combined Phacoemulsification and Different Modes of Diode Laser Therapy in Management of Chronic Angle Closure Glaucoma. A Comparative Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05576493
• Other study ID #: N-68-2022
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 11, 2022
• Est. completion date: December 1, 2023

Study information

• Verified date: August 2023
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

comparing different types of cuclophotocoagulation with cataract extraction to cataract extraction and goniocynechiolysis in cases of chronic angle closure glaucoma

Description:

Evaluation of the safety of MP-TSCPC , CW-TSCPC and endoscopic cyclophotocoagulation when combined with phacoemulsification in cases with CACG Comparing the efficacy of the combined procedures in control of the IOP and the success rate versus lens extraction combined with synechiolysis

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 88
• Est. completion date: December 1, 2023
• Est. primary completion date: October 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients between 20 to 70 years

chronic angle closure glaucoma

Exclusion Criteria:

• Patients in acute attack of angle closure.

• Patients with previous filtering surgery or cycloablative procedure

Related Conditions & MeSH terms

• Angle Closure Glaucoma
• Glaucoma
• Glaucoma, Angle-Closure

Intervention

Procedure:
• phaco+MP-TSCPC
The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
• phaco+TSCPC
The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
• phaco+endocyclophotocoagulation
phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
• phaco GSL
phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.

Locations

Country	Name	City	State
Egypt	Kasr Alainy	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the percentage of intraocular pressure change	measuring the intraocular pressure after 1M, 3M and 6M	6 Months
Secondary	percent change of antiglaucoma medications	the number of medication before and after the procedure	6 Months